Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from PuraPharm Corp. Ltd. ( (HK:1498) ) is now available.
PuraPharm Corporation Limited has called its annual general meeting for 27 May 2026 in Hong Kong, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025. The meeting will also vote on the re-election of several executive, non-executive and independent non-executive directors, authorize the board to set directors’ remuneration, confirm the re-appointment of BDO Limited as auditor, and grant a general mandate for the board to repurchase company shares in accordance with applicable regulations.
These resolutions, if approved, will reaffirm the existing leadership structure, ensure continuity in external auditing arrangements, and provide the board with flexibility to manage the company’s capital structure via share buy-backs. The proposed share repurchase mandate could influence the company’s capital management strategy and shareholder returns, while the re-election of long-serving independent directors underscores an emphasis on governance stability despite ongoing market and regulatory scrutiny of board independence.
More about PuraPharm Corp. Ltd.
PuraPharm Corporation Limited is a Cayman Islands-incorporated company listed in Hong Kong, operating in the pharmaceutical and healthcare sector. It focuses on traditional Chinese medicine and related products, serving markets where demand for TCM-based healthcare solutions is growing.
Average Trading Volume: 229,365
Technical Sentiment Signal: Sell
Current Market Cap: HK$160.5M
For an in-depth examination of 1498 stock, go to TipRanks’ Overview page.